The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 15 - 2024 |
doi: 10.3389/fmicb.2024.1519319
Effectiveness of Antimicrobial Agent Combinations Against Carbapenem-Producing Klebsiella pneumoniae with KPC variants in China
Provisionally accepted- 1 Department of clinical laboratory, Tianjin First Central Hospital, Tianjin, China
- 2 Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
- 3 Suzhou Key Laboratory of Pathogen Bioscience and Anti-infective Medicine, School of Biology & Basic Medical Sciences, Suzhou Medical College, Soochow University, Suzhou, China
- 4 College of Animal Science and Technology, Zhejiang Agriculture and Forestry University, Hangzhou, Zhejiang, China
Purpose: Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a global threat to public health. Antimicrobial agent combinations have been promoted as a potential therapeutic strategy for infections. The most effective antimicrobial combinations against CRKP strains producing different carbapenemases are currently unclear, particularly those producing the KPC variant carbapenemases. This study is aimed to evaluate the effectiveness of various antimicrobial agent combinations against CRKP strains with different carbapenemases.Methods: A checkerboard assay involving 24 antimicrobial agent combinations was conducted on 44 strains of carbapenemase-producing CRKP isolated from patients and hospital sewages, of which 13 CRKP strains carried single KPC variants. The 24 antimicrobial combinations were based on meropenem, polymyxin, tigecycline, ceftazidime/avibactam, respectively. The fractional inhibitory concentration (FIC) indexes were calculated for each combination of antimicrobial agents.The distribution of carbapenemases in 44 CRKP strains was as follows: KPC variants (n = 13, 29.5%), KPC-2 (n = 10, 22.7%), metallo-β-lactamases (n = 9, 20.5%), OXA-48-like (n = 12, 27.3%). In the checkerboard assay, the combination of polymyxin and aztreonam exhibited the highest synergistic effect against CRKP strains, with a rate of 95.5% (42/44). This was followed by polymyxin-meropenem at 88.6% (39/44) and polymyxin-levofloxacin at 68.2% (30/44). Additionally, polymyxin -aztreonam combination and polymyxin-meropenem showed the highest sum of synergistic and additive rates of 100% against KPC variant-producing CRKP strains. Notably, ceftazidime/avibactam-based combinations exhibited better synergistic effects on KPC variant-producing CRKP strains compared to other CRKP strains with adjusted P value < 0.05.Our study suggests that the combinations of antimicrobial agent could serve as potential treatment strategies against CRKP infections. Furthermore, the effectiveness of these combinations is influenced by the types of carbapenemases present. Ceftazidime/avibactam-based combinations have showed superior synergistic effects on KPC variant-producing CRKP strains.
Keywords: carbapenem-resistant Klebsiella pneumoniae, Checkerboard Assay, antimicrobial agent combinations, KPC variant, ceftazidime/avibactam-based dual combinations
Received: 29 Oct 2024; Accepted: 30 Dec 2024.
Copyright: © 2024 Liu, Wu, Zhang, Yan, Gu, Zhou, Dong, CAI, Chen and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rong Zhang, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.